Boston-based healthcare investor Tekla Capital Management has led a consortium of new and existing investors to provide Lausanne-based biopharmaceutical company Oculis with a CHF 15.5m series-B funding round extension.
Anna Morrison joins from IFM Investors, where she managed the firm's fund-of-funds programme
Fund's predecessor, Isomer Capital Fund, closed on €150m in February 2016
Funding will be used to hire more staff, support product development and meet customer demand
True Core VII provides seed and early-stage capital, while True Select IV provides follow-on capital